VISCOMI, Giuseppe Claudio,CHELAZZI, Laura,GREPIONI, Fabrizia,BRAGA, Dario,KINDT, Maddalena
申请号：
IBIB2013/055448
公开号：
WO2014/006576A1
申请日:
2013.07.03
申请国别(地区):
IB
年份:
2014
代理人:
摘要：
The object of the present invention concerns rifaximin compositions comprising amino acids, characterized in that they increase rifaximin solubility in aqueous solutions. Rifaximin compositions comprising amino acids are useful in the treatment of disease wherein amino acids and rifaximin are efficacious. The present invention relates to pharmaceutical compositions comprising rifaximin or one of the pharmaceutically acceptable salts thereof and one or more amino acid(s), wherein the molar ratio between the amino acid(s) and rifaximin is comprised between 1:1 and 10:1, preferably between 1:1 and 5:1, together with pharmaceutically acceptable excipients. Moreover, the present invention relates to rifaximin crystals characterized in that they are obtained by means of a process comprising: a) dissolution of the compositions of rifaximin and amino acids, wherein amino acids and rifaximin are in a molar ratio comprised between 1:1 and 10:1 according to Claim 1, in solutions formed by ethanol/water, in a volumetric ratio comprised between 1:1 and 1:10 (v/v)； b) evaporation of the solution obtained in step a) at temperatures comprised between room temperature and 40°C, in a time period comprised between 1 and 10 days； wherein the resulting crystals have monoclinic space group P21 and cell parameters comprised in the ranges: a: 13.7(1)-13.8(1) Å； b: 19.7(1)-19.9 (1) Å； c: 16.4(6)-16.6(6) Å； β: 92.1 (1)-91.9(1) deg.La présente invention concerne des compositions de rifaximine comprenant des acides aminés, caractérisées en ce qu'elles augmentent la solubilité de la rifaximine dans des solutions aqueuses. Les compositions de rifaximine comprenant des acides aminés sont utiles dans le traitement de maladies contre lesquelles les acides aminés et la rifaximine sont efficaces. La présente invention concerne des compositions pharmaceutiques comprenant de la rifaximine ou l'un de ses sels pharmaceutiquement acceptables et un ou plusieurs acides aminés, dans lesquelles le rapport mol
